Corynebacterium Diphtheriae Infection
Conditions
Keywords
Cutaneous, Diphteria
Brief summary
Toxigenic cutaneous diphtheria is a notifiable disease that is re-emerging in the world and particularly in France. A better description of the epidemiological characteristics, as well as a refinement of the clinical characteristics of patients with cutaneous diphtheria, are essential to better understand this pathology, which has important public health issues and whose diagnosis absence can have catastrophic consequences for the patient and their contacts. Microbiological data (species identification, toxigenicity or not, resistance profile...) will be transmitted by the national reference center for corynebacteria of the diphtheriae complex and then caregivers who have managed the corresponding patients with cutaneous diphtheria will be contacted.
Interventions
OTHERCharacteristics description
Caregivers who follow the patients of the study group will be contacted to collect these patients clinical and epidemiological characteristics
Sponsors
Centre d'Epidémiologie et de Santé Publique des Armées
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Culture or PCR positive skin samples for corynebacteria diphtheria, ulcerans, pseudotuberculosis, belfantii or rouxii * Patient living in metropolitan France
Exclusion criteria
\- Patient opposition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients epidemiological data description | 3 months | Epidemiological data will be collected to describe the studied population (age, sex, place of birth, vaccination status...) |
| Patients clinical data description | 3 months | Clinical data will be collected to describe the studied population (history, description of lesions, disease evolution, complications...) |
| Patients microbiological data description | 3 months | Microbiological data will be collected to describe the studied population (species identification, toxigenicity, presence of a co-infection...) |
| Patients therapeutic data description | 3 months | Therapeutic data will be collected to describe the studied population (antibiotic therapy, duration of treatment, search for an eradication a posteriori...) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of post-infection serological sampling to national recommendations issued by the High Committee of Public Health | 3 months | Whether a post-infection serological sampling was performed or not will be collected. |
| Comparison of antibiotic therapy duration to national recommendations issued by the High Committee of Public Health | 3 months | Duration of antibiotic therapy implemented by clinicians will be compared to national recommendations |
| Comparison of patient isolation procedures to national recommendations issued by the High Committee of Public Health | 3 months | Patient isolation or not will be collected. |
| Comparison of immunization status monitoring to national recommendations issued by the High Committee of Public Health | 3 months | Monitoring of immunization status or not will be collected |
| Comparison of patient post infection vaccination status to national recommendations issued by the High Committee of Public Health | 3 months | Post-infection vaccination or not will be collected |
| Comparison of patient microbiological follow-up to national recommendations issued by the High Committee of Public Health | 3 months | Microbiological follow-up with eradication research or not will be collected. |
Countries
France
Outcome results
None listed